Fujiki Hirota, Sueoka Eisaburo, Watanabe Tatsuro, Suganuma Masami
Department of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, Nabeshima, Saga, 849-8501, Japan,
J Cancer Res Clin Oncol. 2015 Sep;141(9):1511-22. doi: 10.1007/s00432-014-1899-5. Epub 2014 Dec 28.
In 2008, we reported that 10 Japanese-size cups of green tea daily, supplemented with tablets of green tea extract (GTE), reduced the recurrence of colorectal adenoma by 51.6% in patients after polypectomy. Based on these results, we paid special attention to Japanese cancer patients, who consume green tea every day and are administered anticancer drugs. This encouraged us to study whether the combination of green tea catechins and anticancer drugs has the potential to enhance the efficacy of the drugs.
The combination of GTE and NSAIDs synergistically inhibited tumor development in rodents through the activation of the GADD153-DR5-TRAIL apoptotic pathway. Since then, this study was further extended by various investigators to the combinations of EGCG and other green tea catechins with anticancer compounds, the latter of which include NSAIDs, phytochemicals, and anticancer drugs. In order to demonstrate whether diversity of the combinations would generally induce synergistic anticancer effects on numerous human cancer cell lines, we studied the results of 42 in vitro combination experiments and the synergistic inhibition of tumor volume of 13 combination experiments using xenograft mouse models, which were previously reported by other investigators. The various combinations of EGCG and anticancer compounds induced similar synergistic anticancer effects for both in vitro and in vivo experiments, and showed an average reduction in tumor volume by 70.3%. Considering the evidence showing that treatment with EGCG inhibited self-renewal of cancer stem cells, the combination shows a great advantage.
Green tea is a cancer preventive for humans, showing a new trend of green tea catechins as synergists with anticancer compounds.
2008年,我们报告称,每天饮用10杯日本标准量的绿茶,并辅以绿茶提取物(GTE)片剂,可使息肉切除术后患者的结直肠腺瘤复发率降低51.6%。基于这些结果,我们特别关注每天饮用绿茶并接受抗癌药物治疗的日本癌症患者。这促使我们研究绿茶儿茶素与抗癌药物的组合是否有增强药物疗效的潜力。
GTE与非甾体抗炎药(NSAIDs)的组合通过激活GADD153-DR5-TRAIL凋亡途径,协同抑制啮齿动物的肿瘤发展。从那时起,不同的研究人员进一步扩展了这项研究,将表没食子儿茶素没食子酸酯(EGCG)和其他绿茶儿茶素与抗癌化合物组合,后者包括NSAIDs、植物化学物质和抗癌药物。为了证明这些组合的多样性是否通常会对众多人类癌细胞系产生协同抗癌作用,我们研究了42项体外组合实验的结果以及13项使用异种移植小鼠模型的组合实验对肿瘤体积的协同抑制作用,这些实验此前已由其他研究人员报道。EGCG与抗癌化合物的各种组合在体外和体内实验中均产生了类似的协同抗癌效果,肿瘤体积平均减少了70.3%。鉴于有证据表明EGCG治疗可抑制癌症干细胞的自我更新,这种组合显示出巨大优势。
绿茶对人类具有防癌作用,显示出绿茶儿茶素作为抗癌化合物增效剂的新趋势。